Physician profile
Sumit Patel
NPI 1013316652
$467.75
in general payments reported to CMS, 2019-2025
10 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.77 · 2023: $24.45 · 2024: $43.90 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452 · Education: $3.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.66 |
| Education | $3.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $152.47 | 2025 | Renal - Pd, Renal - Acute |
| Otsuka America Pharmaceutical, INC. | $87.53 | 2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals Lp | $58.96 | 2025 | Farxiga |
| Aurinia Pharma U.S., INC. | $51.31 | 2023-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $31.75 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $27.13 | 2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $26.15 | 2025 | Tarpeyo |
| Ardelyx, INC. | $16.36 | 2025 | Ibsrela |
| Getinge USA Sales, LLC | $12.77 | 2019 | |
| Travere Therapeutics, INC. | $3.32 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.